NCAPD2 and lung cancer: Similarly, the expression of NCAPD2 was considerably associated with poor survival in breast cancer (OS: P = 0.011, RFS: P = 0.00094, DMFS: P = 7.4E-06), OV (OS: P = 0.0086, PFS: P = 2E-04), lung cancer (OS: P = 0.00053), gastric cancer (OS: P = 0.013, FP: P = 0.00025) and liver cancer (OS: P = 3E-05, RFS: P = 0.005, PFS: P = 0.00079, DSS: P = 8.9E-05) (Fig. 3C).